Amgen Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +20

Amgen Inc. $AMGN Stock Holdings Boosted by Bessemer Group Inc.

AI-generated analysis

📈 Bessemer Group Inc. increased its Amgen holdings by 9.9% to 32,013 shares worth $11.26 million during the first quarter.

📊 Robeco Institutional Asset Management B.V. lifted its position by 10.0% in Q4, now owning 481,453 shares valued at $157.58 million.

💰 Fideuram Intesa Sanpaolo Private Banking S.P.A. and Robinhood Asset Management LLC acquired new stakes worth approximately $22.44 million and $17.53 million respectively in Q4.

📉 Wall Street Zen downgraded Amgen from 'buy' to 'hold' on June 27th, while Daiwa Securities cut its price target from $410 to $390.

🚀 Freedom Capital upgraded Amgen to a 'strong-buy' rating on May 7th, contrasting with the mixed analyst consensus.

💵 Amgen reported Q1 EPS of $5.15, beating estimates by $0.38, and revenue of $8.62 billion, up 5.8% year-over-year.

📈 The company achieved a net margin of 20.96% and a return on equity of 137.41% in the most recent quarter.

🎯 Amgen set FY 2026 EPS guidance between $21.70 and $23.10, slightly below analyst forecasts of $22.31.

📉 Insider SVP Nancy A. Grygiel sold 1,237 shares for $400,454 on May 4th, reducing her ownership by 15%.

🏢 Institutional investors own 76.5% of Amgen's outstanding stock as of the latest filings.

Bullish Signals
  • Amgen beat quarterly earnings expectations with $5.15 EPS versus a consensus of $4.77, demonstrating strong operational performance.
  • Revenue grew by 5.8% year-over-year to reach $8.62 billion, indicating continued demand for the company's biologic medicines.
  • The company maintains robust profitability metrics with a net margin of 20.96% and an impressive return on equity of 137.41%.
  • Multiple institutional investors including Bessemer Group, Robeco, and Robinhood increased their stakes, signaling confidence in the stock's long-term prospects.
  • Freedom Capital upgraded Amgen to a 'strong-buy' rating, adding to the bullish sentiment from other analysts.
Risk Factors
  • Wall Street Zen downgraded Amgen from a 'buy' to a 'hold' rating, reflecting some caution among analysts regarding current valuation or growth prospects.
  • Daiwa Securities lowered its price target from $410.00 to $390.00, suggesting potential downside pressure or revised expectations for the stock.
  • Amgen's full-year 2026 EPS guidance of $21.70-$23.10 is below analyst forecasts of $22.31, indicating a conservative outlook from management.
  • An insider sale by SVP Nancy Grygiel, who reduced her holdings by 15%, may signal a lack of immediate confidence at the executive level, though this is a small position relative to total shares.
Full Analysis
Amgen Inc. (NASDAQ: AMGN) saw increased institutional interest in the first quarter of 2026, led by Bessemer Group Inc., which boosted its holdings by 9.9% to own 32,013 shares valued at $11.26 million. Other major funds including Robeco Institutional Asset Management B.V., Fideuram Intesa Sanpaolo Private Banking S.P.A., and Robinhood Asset Management LLC also acquired new stakes or significantly increased their positions during the fourth quarter, with institutional ownership standing at 76.5%. Analyst sentiment remains mixed following a recent earnings beat where Amgen reported $5.15 EPS against a consensus of $4.77 and revenue of $8.62 billion, up 5.8% year-over-year. While Wall Street Zen downgraded the stock to a 'hold' and Daiwa Securities lowered its price target, other firms like Freedom Capital upgraded it to a 'strong-buy,' resulting in a consensus rating of 'Hold' with a price target of $356.62. Financially, Amgen maintains strong profitability with a net margin of 20.96% and a return on equity of 137.41%. The company has set full-year 2026 EPS guidance between $21.70 and $23.10, slightly below analyst forecasts of $22.31. Trading at $366.29, the stock carries a market cap of $197.69 billion and a P/E ratio of 25.49, while an insider sale by SVP Nancy Grygiel was disclosed in SEC filings.